Latest Granulocyte macrophage colony-stimulating factor Stories
Mycobacterium tuberculosis is a major cause of death worldwide, and a formidable foe.
An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer.
Joseph Poole, M.D., Ph.D., of the Emory University School of Medicine, Atlanta, and colleagues studied whether therapy with granulocyte-macrophage colony stimulating factor (GM-CSF), an agent that functions as a white blood cell growth factor, would improve walking performance in patients with symptomatic peripheral artery disease (a form of vascular disease in which there is partial or total blockage of an artery, usually one leading to a leg or arm).
Patients with advanced chronic lymphocytic leukemia (CLL) often receive donor transplants that effectively "reboot" their own immune defenses, which then attack and potentially cure the hard-to-treat disease.
The research relates to a family of molecules firstly discovered in Melbourne that applied to blood cell development.
Growth factors shown to cure Alzheimer’s disease in a mouse model and administered to cancer patients as part of their treatment regimen were linked to significant improvements in the patients’ cognitive function following stem cell transplantation.
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- GeoVax Labs, Inc.
ATLANTA, June 8, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX) announced today the publication of the results of preclinical testing of a simian prototype of its 2nd generation HIV/AIDS vaccine.
- Withering but not falling off, as a blossom that persists on a twig after flowering.